Skip to main content

Table 1 Initial demographic parameters of the patients in the intention-to-treat population

From: Effects of pentoxifylline on proteinuria and glucose control in patients with type 2 diabetes: a prospective randomized double-blind multicenter study

  Placebo (n = 87) Pentoxifylline (n = 87) P-value
Age (years) 63.8 ± 9.4 63.7 ± 10.1 0.972
Sex (M/F) 56/31 47/40 0.217
Duration of diabetes (years) 12.6 ± 8.1 12.4 ± 8.3 0.917
BMI (kg/m2) 25.4 ± 3.5 26.0 ± 3.1 0.259
Systolic BP (mmHg) 127.8 ± 11.9 127.6 ± 14.1 0.938
Diastolic BP (mmHg) 74.0 ± 8.9 76.2 ± 10.4 0.141
Statin treatment (%) 56.3 50.0 0.448
Diabetes medication    
 Sulfonylurea (%) 59.8 62.8 0.755
 Metformin (%) 83.9 86.0 0.832
 Thiazolidinedione (%) 5.7 7.0 0.766
 DPP-4 inhibitor (%) 25.3 25.6 1.000
 Insulin (%) 13.8 16.3 0.676
  1. Data are presented as means ± standard deviation (SD), or numbers (percentage)
  2. BMI body mass index, BP blood pressure, DPP-4 dipeptidyl peptidase 4
  3. The independent t-test was used to compare continuous variables between the groups. The χ2 test was implemented for categorical data